Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00695864 · ClinicalTrials.gov registry record · NA

Effect of Ondansetron for Withdrawal Symptoms

A NA study of Substance Withdrawal Syndrome, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT00695864 is a NA study of Substance Withdrawal Syndrome that has completed, run by Stanford University. The registered enrollment target is 31 participants, below the 186-participant average among 3 other Substance Withdrawal Syndrome trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00695864, a NA study of Substance Withdrawal Syndrome, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve withdrawal symptoms experienced while the patient is being weaned off opioid medications. This medication has shown anecdotal evidence of being affective for the treatment of withdrawal symptoms and we hope to determine whether this is affective.

Interventions

  • DRUG Ondansetron and Placebo crossover

Study Locations (1)

California

  • Stanford University School of Medicine - Stanford

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2008-05
Est. Completion 2009-07
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT00695864

The ClinicalTrials.gov registry entry for NCT00695864 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 3 other Substance Withdrawal Syndrome trials with a reported enrollment target (83% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Substance Withdrawal Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Ondansetron and Placebo crossover is the first listed.

NCT00695864 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00695864 about?

NCT00695864 is a clinical study titled "Effect of Ondansetron for Withdrawal Symptoms". We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve withdrawal symptoms experienced while the patient is being weaned off opioid medications. This medication has shown anecdotal evidence of being affective for the treatment of withdrawal symptoms and we hope to...

What is the current status of trial NCT00695864?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2008-05. Estimated completion is 2009-07.

What conditions does trial NCT00695864 study?

This clinical trial studies the following conditions: Substance Withdrawal Syndrome.

What interventions are being tested in trial NCT00695864?

The interventions under investigation include: Ondansetron and Placebo crossover (DRUG).

Who is sponsoring clinical trial NCT00695864?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00695864 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Withdrawal Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.